Barclays Increases IDEXX Laboratories (NASDAQ:IDXX) Price Target to $655.00

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) had its target price lifted by equities research analysts at Barclays from $605.00 to $655.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 14.45% from the stock’s current price.

Other analysts have also issued reports about the company. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $500.00 to $460.00 and set a “hold” rating on the stock in a research note on Monday, October 30th. BNP Paribas assumed coverage on IDEXX Laboratories in a research note on Thursday, December 7th. They set an “outperform” rating and a $602.00 price objective on the stock. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research note on Friday, January 5th. Finally, The Goldman Sachs Group boosted their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $591.50.

Check Out Our Latest Research Report on IDXX

IDEXX Laboratories Stock Up 0.9 %

IDXX stock opened at $572.31 on Tuesday. The stock’s fifty day simple moving average is $536.97 and its two-hundred day simple moving average is $491.13. The company has a current ratio of 1.57, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. IDEXX Laboratories has a 1-year low of $372.50 and a 1-year high of $579.68. The stock has a market cap of $47.53 billion, a P/E ratio of 56.83, a P/E/G ratio of 3.16 and a beta of 1.25.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last issued its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.20. The firm had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The business’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 earnings per share. Analysts expect that IDEXX Laboratories will post 11.08 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In other news, EVP James F. Polewaczyk sold 11,636 shares of the company’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $521.79, for a total value of $6,071,548.44. Following the completion of the transaction, the executive vice president now directly owns 10,050 shares in the company, valued at approximately $5,243,989.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP James F. Polewaczyk sold 11,636 shares of the stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $521.79, for a total transaction of $6,071,548.44. Following the completion of the sale, the executive vice president now directly owns 10,050 shares in the company, valued at approximately $5,243,989.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 7,128 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $513.05, for a total value of $3,657,020.40. Following the sale, the chief executive officer now owns 79,233 shares of the company’s stock, valued at $40,650,490.65. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Panagora Asset Management Inc. increased its position in IDEXX Laboratories by 50.3% during the 1st quarter. Panagora Asset Management Inc. now owns 3,232 shares of the company’s stock valued at $1,768,000 after buying an additional 1,081 shares in the last quarter. Raymond James Trust N.A. increased its position in IDEXX Laboratories by 26.8% during the 1st quarter. Raymond James Trust N.A. now owns 1,624 shares of the company’s stock valued at $888,000 after buying an additional 343 shares in the last quarter. Cetera Investment Advisers increased its position in IDEXX Laboratories by 77.1% during the 1st quarter. Cetera Investment Advisers now owns 3,675 shares of the company’s stock valued at $2,010,000 after buying an additional 1,600 shares in the last quarter. Moors & Cabot Inc. increased its position in IDEXX Laboratories by 3.0% during the 1st quarter. Moors & Cabot Inc. now owns 1,757 shares of the company’s stock valued at $961,000 after buying an additional 52 shares in the last quarter. Finally, Sequoia Financial Advisors LLC increased its position in IDEXX Laboratories by 15.6% during the 1st quarter. Sequoia Financial Advisors LLC now owns 992 shares of the company’s stock valued at $543,000 after buying an additional 134 shares in the last quarter. Institutional investors own 86.85% of the company’s stock.

IDEXX Laboratories Company Profile

(Get Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Recommended Stories

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.